ORTHO-NOVUM 7 Drug Patent Profile
✉ Email this page to a colleague
When do Ortho-novum 7 patents expire, and what generic alternatives are available?
Ortho-novum 7 is a drug marketed by Ortho Mcneil Pharm and Janssen Pharms and is included in two NDAs.
The generic ingredient in ORTHO-NOVUM 7 is ethinyl estradiol; norethindrone. There are twenty-six drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ORTHO-NOVUM 7?
- What are the global sales for ORTHO-NOVUM 7?
- What is Average Wholesale Price for ORTHO-NOVUM 7?
Summary for ORTHO-NOVUM 7
US Patents: | 0 |
Applicants: | 2 |
NDAs: | 2 |
DailyMed Link: | ORTHO-NOVUM 7 at DailyMed |
US Patents and Regulatory Information for ORTHO-NOVUM 7
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ortho Mcneil Pharm | ORTHO-NOVUM 7/14-21 | ethinyl estradiol; norethindrone | TABLET;ORAL-21 | 019004-001 | Apr 4, 1984 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Janssen Pharms | ORTHO-NOVUM 7/7/7-28 | ethinyl estradiol; norethindrone | TABLET;ORAL-28 | 018985-002 | Apr 4, 1984 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Ortho Mcneil Pharm | ORTHO-NOVUM 7/14-28 | ethinyl estradiol; norethindrone | TABLET;ORAL-28 | 019004-002 | Apr 4, 1984 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Janssen Pharms | ORTHO-NOVUM 7/7/7-21 | ethinyl estradiol; norethindrone | TABLET;ORAL-21 | 018985-001 | Apr 4, 1984 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |